The Serious Transfusion Incident Reporting (STIR) system operates under the Blood Matters program, a joint initiative between the Victorian Department of Health and Lifeblood.
Tuesday 17 September was World Patient Safety Day, with the theme ‘Improving diagnosis for patient safety’, in recognition of the critical importance of correct and timely diagno
According to the National Safety and Quality Health Care Standards (NSQHS), informed consent is “a person’s decision, given voluntarily, to agree to a healthcare treatment, procedure or other
The European Society of Cardiology (ESC) updated ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
There’s a lot of debate and controversy, and perhaps even fear, about the use of artificial intelligence (AI) in medicine. And the question is, what will the role of AI in transfusion medicine be?
To explore this, we used GPT-3.5 to write an article about a publication in the October edition of Transfusion journal on the use of AI in transfusion medicine.
Here’s what it came up with. We’ll let you be the judge.
The AABB commissioned and funded updated red blood cell transfusion guidelines through the AABB Clinical Transfusion Medicine Committee, published in JAMA in October 2023.
We are writing to inform you of upcoming changes we are making to Lifeblood’s blood component label. The label changes include the introduction of an ISBT128 2D DataMatrix and the removal of the Codabar Transition Zone, on 30 November 2025.
With these changes, the blood component label will look different and Health Providers still using the Codabar Transition Zone (bottom section), will need to adopt ISBT128 labelling by 30 November 2025.
In Australia, from December 2000 until discontinuation in July 2022, Lifeblood indefinitely deferred people who spent more than 6 months in the United Kingdom during the variant Creutzfeldt–Jakob disease (vCJD) risk period, 1980–1996 to mitigate the potential blood safety risk.
